Currently, Denosumab, an FDA-approved human monoclonal antibody to RANKL, is the first line osteoporosis drug.41 It also shows great promise in other diseases, such as bone tumors and autoimmune diseases. This evidence concerns the gene TNFSF11 and autoimmune disease.